Company intelligence / Profile preview

Newish Technology (Beijing) Co., Ltd.

Beijing, Beijing Shi, Chinabmsscience.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Currently conducting clinical trials for multiple vaccine candidates including NWRD09 (HPV-16 targeted mRNA vaccine) in HPV-16 positive and HPV-16 related cervical, vaginal, and vulvar intraepithelial neoplasia patients and HPV-16 related cervical cancer patients. Also testing NWRD08 in HPV16/18 positive cervical HSIL patients.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA vaccinemRNA vaccineTherapeutic vaccineProphylactic vaccineTCR therapy
Industry: Biotech

Drug pipeline

4 assets

NWRD09

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Newish Technology (Beijing) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newish Technology (Beijing) Co., Ltd..

Explore the full profile